Abstract 227P
Background
C-type lectin superfamily protein LLT1 interacts with CD161 on NK cells and facilitates tumor immune escape. Disruption of LLT1-CD161 with anti LLT1 antibody, ZM008 activates immune cells and kills cancer cells. This study aims to identify new biomarkers to classify specific patient population in ZM008 clinical studies.
Methods
TCGA transcriptome data was used to understand expression of LLT1 in 33 cancers. Correlation analysis was performed to compare LLT1 expression with immune gene signatures. Genomic cancer markers (TMB, MATH, MMR and MSI) status were determined using “Maftools” and “MSI sensor”. Univariate Cox proportional hazard regression analysis (SURVIVAL) was used to measure patient survival.
Results
High expression of LLT1 was found in 11 different cancers. CIBERSORT analysis revealed significant immune cell infiltration (activated NK or CD8+ T) in TME. However, LLT1 expression in multiple cancers is negatively correlated with proinflammatory gene signatures (IL-2, IL-6, EOMES, and LAMP1 etc.), positively correlated with immune exhaustion markers PD1, LAG3, TIM3, TIGIT, ICOS and immune suppressive signals (high Treg cells and CD33+ MDSC; p <0.05). These data suggest immune suppressive “Cold tumor” phenotype associated with LLT1 expressing cancers. Further, immune check point predictors analysis in LLT1 positive tumors suggests positive correlation with high TMB score in COAD, UCEC and KICH; MSI score is elevated in PRAD and COAD; MMR genes expression is negatively correlated in COAD, KICH, BRCA, HNSC, KIRC, LUAD and PRAD; lastly, MATH score is correlated for GBM patients only (p <0.05). Subsequently, significant hazard ratios of 1.115, 2.114 and 1.067 were observed only for COAD, KICH and KIRC, respectively (p < 0.05).
Conclusions
The transcriptome data analysis revealed LLT1 expression is associated with immune repressive TME in multiple cancers, suggesting therapeutic significance of ZM008. Multiple anti-inflammatory gene signatures could be useful in stratifying patients for ZM008 treatment. In addition, TMB & MSI scores and MMR gene expression could be monitored as potential biomarkers in phase I clinical trials with ZM008.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zumutor Biologics.
Funding
Zumutor Biologics.
Disclosure
I. Garcia Ribas: Other, Personal, Advisory role, Independent senior medical advisor: Zumutor. All authors have declared no conflicts of interest.
Resources from the same session
206P - WAYFIND-R: A global, real-world database of patients (pts) with a solid tumour profiled with next-generation sequencing (NGS)
Presenter: Jean-Yves Blay
Session: Poster session 01
207P - Palbociclib (P) in patients (pts) with solid tumors with CDK4 or CDK6 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
Presenter: Maged Khalil
Session: Poster session 01
208P - Identification of BCOR mutation as a novel predictor of immunotherapy efficacy in gastrointestinal tumors
Presenter: Wuping Wang
Session: Poster session 01
209P - Molecular atlas of copy number variation(CNV) in lung cancer with brain metastases
Presenter: Xianfeng Zhang
Session: Poster session 01
210P - Lung tumour vascularity is a risk factor for survival in NSCLC patients undergoing surgery
Presenter: Andrea Riccardo Filippi
Session: Poster session 01
211P - Cost-efficient detection of NTRK1, NTRK2 and NTRK3 gene rearrangements using the test for 5’/3’-end unbalanced expression: The analysis of 8075 patients
Presenter: Evgeny Imyanitov
Session: Poster session 01
212P - Extracellular vesicle miRNA as effective biomarkers for predicting antitumor efficacy in lung adenocarcinoma treated with chemotherapy and checkpoint blockade
Presenter: Si Sun
Session: Poster session 01
213P - Unlocking cancer treatment opportunities by population-based advanced diagnostics in Norway
Presenter: Hege Russnes
Session: Poster session 01
214P - PESSA: A shiny app for pathway enrichment score-based survival analysis in cancer
Presenter: Ying Shi
Session: Poster session 01
215P - Identifying predictors of overall survival among TMB-low cancer patients treated with immune checkpoint inhibitors
Presenter: Camila Xavier
Session: Poster session 01